Abdulkader Rita, Dharmapalaiah Chethana, Rose Ginny, Shand Lynne M, Clunie Gavin P, Watts Richard A
From the Research and Development Department, Department of Rheumatology, The Ipswich Hospital NHS Trust, Ipswich, UK.
J Rheumatol. 2014 May;41(5):858-61. doi: 10.3899/jrheum.130526. Epub 2014 Mar 15.
Late-onset neutropenia (LON) is an adverse effect of rituximab (RTX) in hematological malignancies, a finding that was recently reported in rheumatoid arthritis (RA). The aim of our study was to estimate its incidence in RA.
We retrospectively reviewed complete blood (cell) count of patients with RA who received RTX between October 2007 and July 2011 to identify neutropenia (≤ 1.5 × 10(9)) up to 12 months following RTX.
One hundred eight patients received RTX, median age 64 years (range 25-86). A total of 237 cycles were given. Five patients developed LON after a median of 151 days (71-184). Two developed pneumonia.
LON occurs infrequently after RTX, but can present with infection.
迟发性中性粒细胞减少症（LON）是利妥昔单抗（RTX）治疗血液系统恶性肿瘤时的一种不良反应，最近在类风湿关节炎（RA）中也有此发现。我们研究的目的是评估其在RA中的发生率。
我们回顾性分析了2007年10月至2011年7月期间接受RTX治疗的RA患者的全血细胞计数，以确定RTX治疗后12个月内的中性粒细胞减少症（≤1.5×10⁹）情况。
108例患者接受了RTX治疗，中位年龄64岁（范围25 - 86岁）。共进行了237个疗程。5例患者在中位151天（71 - 184天）后发生LON。2例发生肺炎。
RTX治疗后LON发生率较低，但可能伴有感染。
